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Abstract
Background: Neuropsychiatric symptoms, such as affective symptoms, psychosis, agitation, and apathy are
common among nursing home patients with and without dementia. Treatment with one or more psychotropic
drug is often without explicit clinical indication, despite low treatment efficacy, and potential side effects. We aim to
investigate the multi-psychotropic drug use to identify factors and patient characteristics associated with multi-use.
Methods: We analysed three cohorts from 129 Norwegian nursing homes, collected between 2004 and 2011. Patients
(N = 4739) were assessed with the Neuropsychiatric Inventory – Nursing Home version (NPI-NH), Clinical Dementia
Rating scale, and Physical Self Maintenance Scale. We used ordinal logistic regression to analyse associations between
psychotropics (antidepressants, antipsychotics, anxiolytics, hypnotics, and anti-dementia drugs), patient characteristics,
and neuropsychiatric symptoms.
Results: Patients used on average 6.6 drugs; 27 % used no psychotropics, 32 % one, and 41 % multiple psychotropic
drugs (24 % two, 17 % ≥3). Thirty-nine percent were prescribed antidepressants, 30 % sedatives, 24 % anxiolytics, and
20 % antipsychotics. The total NPI-NH score was associated with multi-use (OR 1.02, 95 % CI 1.02–1.03), and increased
from a mean of 13.5 (SD 16.3) for patients using none, to 25.5 (21.8) for patients using ≥3 psychotropics. Affective
symptoms (depression and anxiety) were most strongly associated with multi-psychotropic drug use (OR 1.10,
95 % CI: 1.09–1.12). Female gender, independency in daily living, younger age, dementia, and many regular drugs were
also associated with multi-use.
Conclusion: Forty-one percent were exposed to multi-psychotropic drug prescriptions. Contrary to current evidence
and guidelines, there is an extensive use of multiple psychotropic drugs in patients with severe NPS and dementia.
Keywords: Dementia, Nursing homes, Neuropsychiatric symptoms, Psychotropic drugs, Antidepressants,
Antipsychotics, Hypnotics, Anxiolytics, Anti-dementia drugs
Background
Neuropsychiatric symptoms (NPS), such as agitation,
psychosis, depression, anxiety, and sleep problems, are
frequently observed among nursing home (NH) patients
with and without dementia [1, 2]. Approximately 90 %
of all people with dementia experience NPS during the
course of the disease [2]. These symptoms are distres-
sing for the patient, the relatives, and the caregivers [3].
People with dementia and NPS are often treated with
psychotropic drugs [4], despite national and inter-
national warnings concerning severe side effects [5, 6].
Recent prevalence rates reflected widespread use; for ex-
ample, Nijk et al. investigated psychotropic drug use in
1322 NH patients from 59 dementia care units in the
Netherlands [7]. Psychotropic drugs were used by 63 %
of the patients, 20 % used two, and 7 % used three or
more. Antipsychotics were the most prevalent of the
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psychotropics, used by 37 % of the patients. Another
cross-sectional study in Belgian NHs showed that 79 %
received psychotropic drugs, of which 54 % were ben-
zodiazepines, and 33 % antipsychotics [8]. Our own
Norwegian trend analysis of six cross-sectional NH co-
horts reported a considerable increase in the use of psy-
chotropics, from 58 % in 1997 to 71 %, in 2009 [9].
Antidepressants increased most (from 32 to 51 %),
followed by anxiolytics and hypnotics (from 15 to 23 %
and 22 %, respectively). The only drugs not increasing
in use were typical antipsychotics and benzodiazepine
hypnotics. The use of two different psychotropics in-
creased from 17 to 22 % and three different drugs from
5 to 11 %.
Psychotropic drugs are often prescribed without
proper symptom assessment, without any clear indica-
tions, and treatment persists for longer than recom-
mended [10]. In addition, review articles investigating
the benefit of psychotropic drugs on NPS found minor
to no treatment effects [4, 11, 12]. Two reviews on the
discontinuation of psychotropics in older adults demon-
strated that discontinuation decreased the incidence of
falls and delirium, and the NPS remained stable [13, 14].
A randomized placebo controlled trial on discontinu-
ation of antidepressants in nursing home patients found
that 86 % could discontinue successfully, however there
was increased depressive symptoms in the intervention
group compared to the controls [15]. Another random-
ized placebo controlled trial on the effect of sertraline in
major depressive episodes in patients with Alzheimer
disease, found that sertraline was superior to placebo in
treating major depressive disorders [16]. These studies
indicate an effect of antidepressants given the right indi-
cation is present, and the importance of weighting po-
tential benefit to harm.
Treatment safety is another important factor because
increased mortality rates were found for people with de-
mentia using atypical antipsychotics [17]. The anti-
psychotic withdrawal trial (DART-AD) on Alzheimer’s
patients from NHs in the UK even showed that survival
for the discontinuation group was not only higher after
12 months, but the difference in survival increased with
time [18]. Increased mortality, and adverse events such
as falls, stroke, and fractures have also been related to
antidepressants; serious side effects were even more
prevalent for selective serotonin reuptake inhibitors
compared to tricyclic antidepressants [19]. Another
population-based study (N = 906 422) showed an in-
creased risk of hip-fractures in users of hypnotics and
anxiolytics [20].
Despite the considerable focus on psychotropic use
in general, little attention has been given to multi-
psychotropic drug use and its association with the se-
verity of NPS. This is of key importance because the
combination of several psychotropics does not neces-
sarily ameliorate the symptoms, and may increase the
risk of interactions and side-effects. In the present
study, we investigated patient characteristics to find
associations to the use of multiple-psychotropic drugs.
We hypothesized that severe NPS and its sub-
syndromes are associated with increased psychotropic
drug use. We expected the factors age, sex, dementia,
and independency in activities of daily living to be as-
sociated with the use of more than one psychotropic.
Method
Subjects
We included patients, 65 years and older, from three
Norwegian cross-sectional multi-centre NH studies from
2004, 2007, and 2011. Norwegian NHs are managed by
the municipalities and are an essential part of the pri-
mary health care system. All patients in the included
wards were eligible if they had lived in the NH for more
than 2 weeks prior to data collection and consented to
participate. Demographics, diagnoses and information
on prescribed medicines were collected from the pa-
tients’ medical records. Standardized interviews of
nurses, who knew the patients well, were used to collect
data on clinical status.
The 2004 cohort included patients in 26 NHs from 18
municipalities in four counties, 1165 patients were eli-
gible, two declined to participate, and 26 were too
young, giving a total of 1137 patients. Data was origin-
ally collected to explore the association between NPS
and psychotropic drug use at different stages of demen-
tia [21]. Before data collection, registered nurses were
trained during a 2-day programme on structured inter-
views for primary caregivers.
The 2007 cohort examined patients living in 63 NHs
in the South-Eastern health region of Norway. In all, 151
wards were included, with 2108 eligible patients, 162
had a stay less than 2 weeks, 3 declined to participate,
and 64 were too young, giving 1879 patients in total.
This study investigated the problematic practice of ad-
ministering medication to patients by concealing them
in food and beverages [22]. Registered nurses received
2 h of training in addition to oral and written instruc-
tions on how to complete data collection. This study did
not collect data on diagnoses.
The 2011 cohort consisted of 23 of the 26 NHs, which
were included in the 2004 cohort, along with 40 new
NHs from 31 municipalities altogether. For patients
assessed in both 2004 and 2011, we used only data from
2004. Altogether, 2385 patients were eligible, 98 were
also assessed in 2004, 423 declined to participate, 17
died before assessment, 33 were terminally ill or had a
serious somatic condition, one moved, 53 were excluded
without giving a cause, and 37 were too young, giving
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1723 patients. The 2004 procedure for inclusion, educa-
tion and collection of data was used [23].
Outcome measures
The Neuropsychiatric Inventory – NH version (NPI –NH)
is a 12-item proxy rated instrument to assess the fre-
quency and severity of NPS over the last 4 weeks in people
with and without dementia [24]. NPI-NH consists of items
for delusions, hallucination, agitation, depression, anxiety,
euphoria, apathy, disinhibition, irritability, aberrant motor
behaviour, night-time behaviour, and eating disturbances.
Items are scored on frequency (0 to 4 – absent to daily)
and severity for the patient (1 to 3 – mild to severe). Se-
verity and frequency are multiplied to create a sum-score
from 0 to 12 for each item. The Norwegian translation has
good validity and reliability [25]. In this study, items were
clustered into the clinical relevant sub-syndromes, follow-
ing a previous exploratory factor analysis, psychosis (hallu-
cination and delusions), affective symptoms (depression
and anxiety), and agitation (agitation and irritability). Ap-
athy did not cluster with any of the sub-syndromes [26].
The Clinical Dementia Rating Scale (CDR) assesses
the level of dementia [27, 28]. The CDR score is calcu-
lated with an algorithm giving extra weight to memory
problems. CDR scores of 0, 0.5, 1, 2, and 3, indicate no,
possible, mild, moderate, and severe dementia, respect-
ively. In the 2007 cohort CDR 0.5 was scored as 0.
The patients’ dependency in daily living was measured
with the Physical Self-Maintenance Scale (PSMS). The
six items toileting, feeding, dressing, grooming, physical
ambulation, and bathing yield an aggregate score of 6–30;
higher scores indicate higher dependency in activities of
daily living. Good reliability and validity of PSMS has been
reported earlier [29, 30].
Medication and diagnoses
The psychotropic drugs were classified as antipsychotics
(N05A), anxiolytics (N05B), sedatives (N05C), antide-
pressants (N06A), and anti-dementia drugs (N06D) in
the Anatomical Therapeutic Chemical Index (ATC) clas-
ses [31]. “Regular drugs” was a count of the drugs the
patient was prescribed on the day of data collection, pro
re nata drugs were not included in this count. “Regular
drugs without psychotropics” was the number of regular
drugs, when psychotropic drugs were subtracted. The
diagnoses were coded with International Classification
of Diseases – 10th version [32]. Dementia is an aggre-
gate of the diagnoses F00 dementia with Alzheimer, F01
vascular dementia, F02 dementia in other diseases classi-
fied elsewhere, and F03 unspecified dementia.
Statistical methods
Background characteristics and comparisons between the
cohorts were analysed using chi-square for categorical var-
iables, and one-way ANOVA for continuous variables.
The total NPI-NH score was log-transformed in the
ANOVA due to non-normality. Association between CDR
and dementia was tested using chi square test and Phi for
strength of association. The patients were divided into
four ordinal groups according to number of psychotropic
prescriptions (0, 1, 2 and ≥3). We used cumulative odds
ordinal logistic regression with proportional odds analyses
[33] to create odds ratios (OR), 95 % confidence intervals
(CI), and p-values for the association between the pre-
scription of psychotropic drugs and age, gender, severity
of dementia, NPS, dependency in activities of daily living,
regular drugs without psychotropics, and diagnoses. We
created two logistic regression analyses (Analysis 1 and 2)
because the 2007 cohort did not contain information on
Table 1 Demographics of the study population in total and by cohort
Total 2004 2007 2011 P-value
N = 4739 N = 1137 N = 1879 N = 1723
Age, mean (SD) a,b 85.7 (7.0) 85.0 (6.5) 85.9 (7.1) 85.9 (7.1) 0.03
Women, N (%) 3383 (71) 836 (74) 1321 (70) 1226 (71) NS
Regular drugs without psychotropics, mean (SD)a,b,c 5.2 (2.9) 4.7 (2.8) 5.1 (2.9) 5.7 (3.0) <0.001
Dementia (CDR), N (%) <0.001
No 497 (11) 37 (3) 406 (22) 54 (3)
Questionable 388 (8) 183 (16) 0 (0) 205 (12)
Mild 686 (15) 225 (20) 163 (9) 298 (18)
Moderate 1336 (28) 306 (27) 529 (28) 501 (30)
Severe 1786 (38) 382 (34) 768 (41) 636 (38)
Dependency, mean (SD)b,d 18.1 (5.4) 18.0 (5.3) 18.5 (5.5) 17.7 (5.3) <0.001
NPI-NH total score, mean (SD) 17.5 (18.7) 18.5 (19.2) 16.1 (17.6) 18.5 (17.6) 0.03
ANOVA for continuous and X2 for categorical data
NPI-NH neuropsychiatric inventory – nursing home version, SD standard deviation, NS not significant
CDR Clinical Dementia Rating scale 1 to 3, asignificant between 2004 and 2007, bsignificant between 2004 and 2011, csignificant between 2007 and 2011, dhigher
scores indicates more dependency in daily living
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diagnoses and NPS-NH total score and the sub-
syndromes can cause a potential multicollinearity prob-
lem. Both regression analyses included age, gender, regular
drugs without psychotropics, dependency, and cohort.
Analysis 1 also contained severity of dementia measured
by CDR and the sub-syndromes of NPS (affective symp-
toms, agitation, psychosis, and apathy). Analysis 2 covered
the NPI-NH total score and the most frequent diagnoses.
We adjusted for cohort year in the analyses due to differ-
ences in the demographics between the cohorts; the co-
hort was included as a nominal independent variable
(2011 as reference). Both analyses met the assumption of
proportional odds and there was no multicollinearity. Stat-
istical significance was set to p < 0.05. IBM SPSS statistics
version 22.0 (IBM Corp, Armonk, NY, USA) was used to
perform the analyses.
Results
In total, 4739 participants were included from three co-
horts of 129 Norwegian NHs, assessed in 2004, 2007,
and 2011. Demographics and clinical characteristics
stratified by cohort-year are shown in Table 1. The mean
Table 2 Clinical characteristics associated with psychotropic drug use, crude and adjusted values for Analysis 1 and 2
Psychotropic drugs Crude Adjusted
0 1 2 ≥3 OR 95 % CI OR 95 % CI
Patients, % 27.3 32.2 23.4 17.1
Factors included in Analyses 1 and 2
Age, mean (SD) 86.7 (6.9) 86.1 (7.0) 85.3 (6.8) 83.9 (6.8) 0.97** 0.96–97 0.97** 0.96–0.98
Femalesa, % 68.8 72.4 72.5 72.8 1.13* 1.01–1.27 1.20* 1.06–1.36
Dependency, mean (SD) d 18.9 (5.5) 18.1 (5.5) 17.8 (5.2) 17.2 (5.2) 0.97** 0.96–0.98 0.96** 0.95–0.97
Regular drugs without psychotropics, mean (SD) 4.9 (2.8) 5.3 (3.0) 5.5 (2.9) 5.2 (2.9) 1.04** 1.02–1.06 1.05** 1.03–1.07
Analysis 1
Cognitive impairmentb
Noa, % 9.9 11.1 11.0 10.3 1 1
Questionable, % 9.2 7.7 8.2 8.0 0.88 0.70–1.12 1.19 0.91–1.55
Mild, % 13.3 15.6 14.1 15.7 1.03 0.84–1.27 1.23 0.98–1.54
Moderate, % 26.0 28.6 31.1 28.5 1.05 0.87–1.26 1.19 0.97–1.46
Severe, % 41.6 37.1 35.7 37.6 0.89 0.74–1.06 1.15 0.92–1.42
NPI-NH sub-syndromes
Affective symptoms, mean (SD) 1.8 (3.5) 2.6 (4.2) 3.9 (5.2) 5.9 (6.2) 1.** 1.10–1.13 1.10** 1.09–1.12
Agitation, mean (SD) 3.2 (5.2) 3.5 (5.5) 4.4 (6.1) 5.7 (6.5) 1.05** 1.04–1.06 1.02** 1.01–1.03
Psychosis, mean (SD) 1.8 (4.1) 2.3 (4.6) 2.8 (5.0) 4.4 (6.3) 1.06** 1.05–1.07 1.02** 1.01–1.04
Apathy, mean (SD) 1.9 (3.5) 1.8 (3.2) 2.0 (3.4) 2.3 (3.6) 1.02* 1.00–1.03 0.99 0.98–1.01
Analysis 2, 2004 and 2011 cohort
NPI-NH total score 13.5 (16.3) 15.4 (16.8) 19.2 (19.3) 25.5 (21.8) 1.02** 1.02–1.02 1.02** 1.02–1.03
Diagnosesc
Dementia, % 27.4 26.9 26.5 33.3 1.13* 1.01–1.27 1.19* 1.03–1.37
Hypertension, % 14.4 13.5 14.2 12.4 0.93 0.81–1.08 1.01 0.86–1.19
Stroke, % 12.2 9.3 9.2 7.3 0.72** 0.61–0.86 0.89 0.74–1.07
Heart failure, % 9.3 7.8 7.3 7.0 0.82* 0.68–0.99 0.90 0.73–1.11
Atrial fibrillation/flutter, % 8.5 8.3 6.8 5.7 0.78* 0.64–0.94 0.92 0.75–1.13
Angina, % 3.9 4.7 6.1 6.1 1.42* 1.13–1.79 1.60** 1.26–2.04
Osteoporosis, % 5.7 6.0 4.7 4.8 0.85 0.68–1.08 0.91 0.72–1.16
Hip fracture, % 6.1 5.0 4.8 5.3 0.88 0.70–1.10 1.04 0.82–1.33
Diabetes, % 5.8 5.2 5.4 2.8 0.75* 0.59–0.95 0.75* 0.59–0.97
P-values, odds ratios and confidence intervals from cumulative odds logistic regression. Analysis 1 and 2 included age, sex, dependency and total medication. The
factor unique to each analysis is listed below their headlines in the table
NPI-NH neuropsychiatric inventory – nursing home version, SD standard deviation, OR odds ratio, CI confidence interval
aused as reference, bassessed by Clinical Dementia Rating scale, cfrom ICD-codes in patient records, *p-value < 0.05, **p-value < 0.001, dhigher scores indicates more
dependency in daily living
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age was 86 years; 71 % of the patients were women, and
they used on average 6.6 drugs. Age (p = 0.03) and regu-
lar drugs (p < 0.001) differed significantly between the
cohorts, with higher age and more drugs in 2011. De-
mentia (46 %), hypertension (23 %), stroke (16 %), heart
failure (13 %), atrial fibrillation (13 %), osteoporosis
(9 %), hip fracture (9 %), angina (9 %), and diabetes
(8 %) were the most frequent diagnoses in the medical
records. Assessed by CDR, 80 % of the patients had de-
mentia (CDR ≥1). There was a small (Phi = 0.274), but
statistically significant (p < 0.001) association between
dementia according to CDR and a diagnosis of dementia
in the patient records. CDR identified 1307 (98 %) of the
patients with a diagnosis of dementia in the records
(N = 1328). Of the patients with no recorded diagnose
of dementia (N = 3411), 2547 (75 %) were classified
with dementia according to CDR. The mean (SD)
PSMS and NPI-NH scores were 18.1 (5.4) and 17.5 (18.7),
respectively. Dementia, dependency and NPI-NH total
score differed between the cohorts (p < 0.05), with more
dementia and lower dependency in 2011, and lower
NPI-NH score in 2007 (Table 1).
Psychotropic drug use
Almost three out of four received at least one psycho-
tropic drug and two out of five received two or more
(range 0–7) (Table 2). Thirty-nine percent received an-
tidepressants, 30 % sedatives, 24 % anxiolytics, 20 % an-
tipsychotics, and 14 % anti-dementia drugs. The most
frequent psychotropic drug combinations were antide-
pressants and sedatives (14 %), antidepressants and an-
xiolytics (12 %), and sedatives and anxiolytics (11 %).
The most prescribed individual drug was the z-
hypnotic, zopiclone (23 %). This medication was com-
bined with oxazepam in 6 % of the patients, and with
escitalopram in 4 % (Table 3).
Factors associated with multi-psychotropic drug use
The total NPI-NH score was associated with multi-use
(OR 1.02, 95 % CI 1.02–1.03), and increased from a
mean of 13.5 (SD 16.3) for patients using none, to 25.5
(SD 21.8) for patients using ≥3 psychotropics (Table 2).
The sub-syndromes affective symptoms (OR 1.10, 95 %
CI 1.09–1.12), agitation (OR 1.02, 95 % CI 1.01–1.03),
and psychosis (OR 1.02, 95 % CI 1.01–1.04) demon-
strated a significant association as well (Fig. 1). The ad-
justed OR for variables included in both Analysis 1 and
2 were similar and had the same effects; the OR listed
here are from Analysis 1. Female gender (OR 1.20, 95 %
CI 1.06–1.36), independency in daily activities (OR 0.96,
95 % CI 0.95–0.97), younger age (OR 0.97, 95 % CI
0.96–0.98), and more regular drugs without psychotro-
pics (OR 1.05, 95 % CI 1.03–1.07) were all associated
with increased psychotropic drug use. Compared to no
diagnosis of dementia in their records (Analysis 2), having
dementia increased the likelihood of being treated with
multiple psychotropics (OR 1.19, 95 % CI 1.03–1.37)
(Table 2). Poorer cognitive function measured with CDR
was not associated with the use of psychotropics com-
pared to normal cognitive function (Fig. 2). Of the other
frequent diagnoses, diabetes lead to less psychotropics
(OR 0.75, 95 % CI 0.59–0.97), while angina lead to more
(OR 1.60, 95 % CI 1.26–2.04) (Table 2). The 2004 and
2007 had significantly higher risk of multi-use than the
Table 3 Use of psychotropic drug groups, individual
psychotropics, and combinations of psychotropics
ATC code and generic name N = 4739, %
N05A Antipsychotics 19.9
N05A X08 Risperidone 5.6
N05A D01 Haloperidol 3.4
N05A H03 Olanzapine 2.8
N05B Anxiolytics 23.9
N05B A04 Oxazepam 19.2
N05B B01 Hydroxyzine 3.2
N05B A01 Diazepam 2.1
N05C Sedatives 30.5
N05C F01 Zopiclone 23.0
N05C D02 Nitrazepam 3.4
N05C M02 Clomethiazole 2.7
N06A Antidepressants 39.2
N06A B10 Escitalopram 12.5
N06A B04 Citalopram 10.7
N06A X03 Mianserin 7.4
N06D Anti-dementia drugs 13.7
N06D A02 Donepezil 6.8
N06D X01 Memantine 4.7
N06D A03 Rivastigmine 2.0
Combinations of psychotropic drug classes
Antidepressants and sedatives 14.4
Antidepressants and anxiolytics 12.1
Sedatives and anxiolytics 10.6
Antidepressants and antipsychotics 9.1
Two antidepressants 6.2
Combination of specific psychotropic drugs
Zopiclone and Oxazepam 5.6
Zopiclone and Escitalopram 3.5
Zopiclone and Citalopram 3.3
Oxazepam and Escitalopram 3.0
Oxazepam and Citalopram 2.8
Oxazepam and Mianserin 2.5
Zopiclone and Mianserin 2.2
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2011 cohort, with the highest OR for the 2007 cohort (OR
1.65, 95 % CI 1.45–1.89).
Discussion
The present study found that 41 % of Norwegian NH
patients were treated with two or more psychotropic
drugs. Antidepressants (39 %) were most prevalent and
often combined with sedatives (14 %) and anxiolytics
(12 %). In accordance with our hypotheses, patients with
severe NPS, especially depression and anxiety, used
more psychotropics. Female gender, independency in
daily activities, younger age, dementia, and more regular
drugs, were all associated with multi-use.
High prevalence of multiple psychotropic drug use
was also demonstrated by other NH studies. In a Dutch
study, 27 % used two or more psychotropic drugs, and
antipsychotics were the most prescribed drugs (37 %)
[7]. An American study found that 45 % used two or
more psychotropics, and antidepressants were most fre-
quently used (41 %) [34]. A study from Sweden found
that 28 % used ≥3 psychotropics, and 51 % used hyp-
notics [35].
The association between psychotropic drug use and
NPS has been highlighted earlier [7, 36, 37]. This was
supported by our study; we found that severe NPS, espe-
cially affective symptoms and agitation, were related to
multi-use. The use of multiple psychotropic drugs might
indicate that clinicians try to treat a symptom with one
drug, and if the symptom persists, they add another
drug, often with the same indication, without stopping
or re-evaluating the treatment. This can be due to belief
in the additive effect, or to the burden NPS puts on pa-
tients and caregivers, resulting in a pressure from care-
givers to prescribe [37, 38]. The OR for the NPI items
were low, for instance for affective symptoms it was
1.10. This reflects an increase of 10 % in odds of receiv-
ing more psychotropics for every unit change on the
NPI-NH score. This implies that patients with severe
symptoms received considerably more psychotropics.
The current study found that especially patients
with depression and anxiety used more psychotropics.
Indication for the drugs and appropriateness of their
use is beyond the scope of this article. However, both
depression and anxiety are prevalent among NH resi-
dents, and drugs for these conditions are commonly
prescribed [39]. A recent study showed that the anti-
depressants were prescribed for other indications than
depression in 50 % of the cases, and most patients
lacked a diagnostic work-up [40]. Affective symptoms
may have many causes, hence the assessment and
treatment should be adjusted accordingly to avoid
over-prescribing of psychotropics [41]. We also found
independency in daily living to be associated with the
use of more psychotropics. A possible reason for this
could be that patients with high dependency are often
bedridden or so reduced that they are incapable of






















Fig. 1 Difference in neuropsychiatric symptoms for patients using 0, 1, 2 or ≥3 psychotropics. Mean NPI-NH scores (95 % CI) for the sub-
syndromes affective symptoms, agitation and psychosis (left- axis, dotted colored lines), and mean total NPI-NH score (right axis, solid black
line). X-axis represents patients using 0 to ≥3 psychotropic drugs. NPI-NH Neuropsychiatric Inventory – Nursing Home version, CI
confidence interval
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distress as the mobile and active independent pa-
tients. Hence, the independent patients receive more
psychotropics to dampen their symptoms, which
might explain this association. Other studies show di-
vergent associations [34, 36, 42].
Our results showed that people with a diagnosis of de-
mentia in their records use more psychotropics than
those without a diagnosis, despite the consensus that
they should be treated with utmost caution and less psy-
chotropic drugs [41, 43, 44]. An article describing the
2004 cohort found that only 55 % of patients with de-
mentia according to the CDR had a dementia diagnosis
in the medical records in the nursing home [21]. The
weak association between a dementia diagnosis and psy-
chotropics might be an effect of staff blaming the de-
mentia for the NPS, rather than investigation other
causes for these symptoms [12]. Patients with a diagno-
sis of diabetes used fewer psychotropic drugs. This cor-
roborates and extends earlier research that people with a
high Charlson’s Comorbidity Score received fewer anti-
psychotics [45].
Limitations and strengths
There are some limitations to this study. Indications,
duration, or doses were not recorded, nor were pro re
nata medications. These factors, and the cross-sectional
design, made it impossible to assess the appropriateness
and effects of the drugs. We did not know whether the
patient used the drugs because of severe NPS, if the NPS
was reduced by the drugs, or the drugs aggravated NPS.
Another limitation is that the diagnoses listed in the
medical records may be of low quality because of the ab-
sence of a standard of what to report and of sub-optimal
electronic patient records [46]. The use of popular, vali-
dated and reliable assessment scales for NPS, dementia
and ADL [24, 25, 27–30], are a major strength and make
our results comparable to other studies. Age, percentage
of women, drug use, and CDR scores were similar to
other Norwegian nursing home studies [40, 47, 48]. The
large cohort size, including patients from 129 NHs all
over the country, from small and large municipalities,
thus very likely mirrors the Norwegian NH population.
Conclusion
Forty-one percent of NH patients use multiple psycho-
tropic drugs. Severe NPS, especially affective symptoms,
were associated with extensive use. The use of multiple
psychotropic drugs in in patients with dementia is wide-
spread, contrary to current evidence and guidelines.
There is an urgent need to test and implement methods
to optimize prescription procedures for these patients.
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